自2011年以来，林先生一直担任Esco Lifesciences Group的董事长兼首席执行官，是一位在美国、亚洲和欧洲都有着良好业绩的生命科学企业家和投资者。2018年，林先生成立了EVX Ventures，并担任其创始人和管理合伙人。EVX Ventures是一家位于波士顿、新加坡和上海的风险投资公司，专注于在亚洲和美国投资生物技术公司。其投资组合包括Carmine Therapeutics、PairX Bio、Hummingbird Bioscience、Nuevocor、Cargene和Carcell等公司。EVX Ventures还投资于美国和欧洲的生物技术公司，帮助它们与亚洲市场，特别是中国和东南亚的市场建立联系。EVX已经完成了超过1亿美元的资金和制药合作交易。林先生拥有宾夕法尼亚大学沃顿商学院经济学和金融学学士学位。
Mr. XiangQian (XQ) Lin is a seasoned global business leader and a synergistic business partner to entrepreneurial scientists and innovators. Having lived and worked across the US, China, Europe, and Singapore, Mr. Lin has accumulated extensive operating and investment experience around the world, building a strong track record in taking technologies from concepts to commercial realities.
Mr. Lin has served as the Chairman and Chief Executive Officer of the Esco Lifesciences Group since 2011, and is a life sciences entrepreneur and investor with a demonstrated track record across the United States, Asia and Europe. In 2018, Mr. Lin served as the founder and managing partner of EVX Ventures, EVX Ventures, a venture capital firm based in Boston/Singapore/Shanghai, builds and invests in biotech companies across Asia and the US. Portfolio companies include Carmine Therapeutics, PairX Bio, Hummingbird Biosciences, Nuevocor, Cargene, Carcell and others. EVX Ventures also invests in US/European biotech companies, bridging them to the Asian markets, especially China and Southeast Asia. EVX incubated companies have closed over USD 1 billion in follow on funding and pharma partnership deals. Mr. Lin holds a B.Sc. degree in Economics and Finance from the Wharton School of Business, University of Pennsylvania.